Table 4.
Subgroup meta-analysis of the association between ESR1 Xbalpolymorphisms and breast cancer risk.
| Subgroup | GG vs. GA+AA | GG+GA vs. AA | GG vs. AA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I2 (%) | ph# | OR (95%CI) | pOR* | I2 (%) | ph# | OR (95%CI) | pOR* | I2 (%) | ph# | OR (95%CI) | pOR* | |
| Ethnicity | ||||||||||||
| Caucasian | 11.9 | 0.33 | 1.09 (0.96–1.22) | 0.17 | 0.0 | 0.51 | 1.04 (0.97–1.13) | 0.27 | 0.0 | 0.41 | 1.11 (0.98–1.26) | 0.10 |
| Asian | 0.0 | 0.67 | 0.85 (0.62–1.16) | 0.30 | 0.0 | 0.89 | 1.06 (0.94–1.20) | 0.34 | 0.0 | 0.73 | 0.88 (0.64–1.20) | 0.42 |
| Source | ||||||||||||
| PB | 0.0 | 0.66 | 1.04 (0.93–1.17) | 0.46 | 0.0 | 0.76 | 1.05 (0.98–1.12) | 0.15 | 0.0 | 0.75 | 1.07 (0.95–1.20) | 0.27 |
#
P-value from heterogeneity test;
*
P-value from OR test;
**
Analysis on HB is not performed due to the lack of study.